FI955319L - 2-pyridylmethylenepolyazamacrocyclophosphonic acids, their complexes and derivatives for use as antibodies - Google Patents
2-pyridylmethylenepolyazamacrocyclophosphonic acids, their complexes and derivatives for use as antibodies Download PDFInfo
- Publication number
- FI955319L FI955319L FI955319A FI955319A FI955319L FI 955319 L FI955319 L FI 955319L FI 955319 A FI955319 A FI 955319A FI 955319 A FI955319 A FI 955319A FI 955319 L FI955319 L FI 955319L
- Authority
- FI
- Finland
- Prior art keywords
- pyridylmethylenepolyazamacrocyclophosphonic
- complexes
- antibodies
- derivatives
- acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
- G01R33/281—Means for the use of in vitro contrast agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/057,588 US5462725A (en) | 1993-05-06 | 1993-05-06 | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| PCT/US1994/005009 WO1994026275A1 (en) | 1993-05-06 | 1994-05-05 | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI955319A0 FI955319A0 (en) | 1995-11-06 |
| FI955319L true FI955319L (en) | 1995-12-22 |
| FI955319A7 FI955319A7 (en) | 1995-12-22 |
Family
ID=22011534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI955319A FI955319A7 (en) | 1993-05-06 | 1994-05-05 | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, their complexes and derivatives for use as antibodies |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5462725A (en) |
| EP (1) | EP0711300B1 (en) |
| JP (1) | JPH08510245A (en) |
| CN (1) | CN1125905A (en) |
| AT (1) | ATE227297T1 (en) |
| AU (1) | AU678583B2 (en) |
| BG (1) | BG100192A (en) |
| CA (1) | CA2162174A1 (en) |
| CZ (1) | CZ289595A3 (en) |
| DE (1) | DE69431660T2 (en) |
| FI (1) | FI955319A7 (en) |
| HU (1) | HUT74565A (en) |
| LV (1) | LV11430B (en) |
| NO (1) | NO301829B1 (en) |
| PL (1) | PL311643A1 (en) |
| SG (1) | SG46458A1 (en) |
| WO (1) | WO1994026275A1 (en) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409689A (en) * | 1993-08-13 | 1995-04-25 | Concat, Ltd. | MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms |
| DE19523891C1 (en) * | 1995-06-30 | 1996-11-21 | Hoechst Ag | Chiral manganese-triazanonane complexes and process for their preparation |
| CA2251924C (en) * | 1996-04-19 | 2006-05-30 | The Dow Chemical Company | Fluorescent chelates as visual tissue specific imaging agents |
| US7632651B2 (en) | 1997-09-15 | 2009-12-15 | Mds Analytical Technologies (Us) Inc. | Molecular modification assays |
| WO2001019838A1 (en) * | 1999-09-13 | 2001-03-22 | Du Pont Pharmaceuticals Company | Macrocyclic chelants for metallopharmaceuticals |
| EP1362861B1 (en) * | 1999-09-13 | 2005-12-14 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants for metallopharmaceuticals |
| US6685914B1 (en) | 1999-09-13 | 2004-02-03 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants for metallopharmaceuticals |
| WO2003020701A2 (en) * | 2001-09-04 | 2003-03-13 | Texas Tech University | Multi-use multimodal imaging chelates |
| ATE309254T1 (en) | 2001-10-22 | 2005-11-15 | Univ Texas Tech | TISSUE-SPECIFIC FLUORESCENT CHELATES |
| WO2003098232A2 (en) * | 2002-05-17 | 2003-11-27 | Case Western Reserve University | Chemical shift markers for improved wireless fiducial marker tracking |
| US20060210479A1 (en) * | 2004-08-10 | 2006-09-21 | Dow Global Technologies Inc. | Targeting chelants and chelates |
| EP1637524A1 (en) * | 2004-09-20 | 2006-03-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | 10-substituted 1-, 4, 7,-tris (carboxymethyl)-1,4,7,10-tetraazacyclo-dodecane derivative for use as contrast agents |
| NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| CA2581639C (en) * | 2004-09-30 | 2016-07-26 | Molecular Devices Corporation | Luminescent lanthanide complexes |
| RS54163B1 (en) | 2006-05-30 | 2015-12-31 | Genentech Inc. | ANTI-CD22 ANTIBODIES, THEIR IMMUNCONJUGATES AND THEIR USE |
| LT2845866T (en) | 2006-10-27 | 2017-07-10 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| AU2008216495A1 (en) | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-Robo4 antibodies and uses therefor |
| WO2009012256A1 (en) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| DK2176296T3 (en) | 2007-07-16 | 2012-05-21 | Genentech Inc | Anti-CD79B antibodies and immune conjugates and methods of use. |
| DK2247620T3 (en) | 2008-01-31 | 2016-08-22 | Genentech Inc | ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE |
| US8499251B2 (en) | 2009-01-07 | 2013-07-30 | Microsoft Corporation | Virtual page turn |
| CN102471380B (en) | 2009-04-01 | 2015-01-14 | 霍夫曼-拉罗奇有限公司 | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| EP2896404B1 (en) | 2009-06-04 | 2017-08-02 | Novartis AG | Methods for identification of sites for IgG conjugation |
| EP3778917A3 (en) | 2009-12-04 | 2021-06-09 | F. Hoffmann-La Roche AG | Multispecific antibodies, antibody analogs, compositions, and methods |
| MX336109B (en) | 2010-06-03 | 2016-01-08 | Genentech Inc | FORMATION OF IMMUNE-TEP IMAGES OF ANTIBODIES AND IMMUNOCUSES AND USES OF THE SAME. |
| US9000130B2 (en) | 2010-06-08 | 2015-04-07 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| ES2604012T3 (en) | 2012-07-04 | 2017-03-02 | F. Hoffmann-La Roche Ag | Covalently bound antigen-antibody conjugates |
| WO2014006123A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-biotin antibodies and methods of use |
| RU2630664C2 (en) | 2012-07-04 | 2017-09-11 | Ф. Хоффманн-Ля Рош Аг | Theophylline antibodies and methods for their application |
| JP6521464B2 (en) | 2014-01-03 | 2019-05-29 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Covalently linked polypeptide toxin-antibody conjugates |
| US10561737B2 (en) | 2014-01-03 | 2020-02-18 | Hoffmann-La Roche Inc. | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
| KR102278979B1 (en) | 2014-01-03 | 2021-07-19 | 에프. 호프만-라 로슈 아게 | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
| MX2017003123A (en) | 2014-09-12 | 2017-05-12 | Genentech Inc | Cysteine engineered antibodies and conjugates. |
| JP6618539B2 (en) | 2014-12-17 | 2019-12-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Method for enzyme-mediated polypeptide conjugation using sortase |
| JP6998862B2 (en) | 2015-09-25 | 2022-02-04 | エフ．ホフマン－ラ ロシュ アーゲー | Soluble sortase A |
| EP3353314A1 (en) | 2015-09-25 | 2018-08-01 | H. Hoffnabb-La Roche Ag | Transamidation employing sortase a in deep eutectic solvents |
| ES2896475T3 (en) | 2015-09-25 | 2022-02-24 | Hoffmann La Roche | Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof |
| EP3353310B1 (en) | 2015-09-25 | 2020-04-29 | H. Hoffnabb-La Roche Ag | Process for producing thioesters employing a sortase a |
| EP3436578B1 (en) | 2016-03-30 | 2022-01-19 | F. Hoffmann-La Roche AG | Improved sortase |
| WO2018191389A1 (en) | 2017-04-12 | 2018-10-18 | Roche Sequencing Solutions, Inc. | A method for sequencing reaction with tagged nucleoside obtained via pictet spengler reaction |
| KR102696526B1 (en) | 2017-07-13 | 2024-08-19 | 에프. 호프만-라 로슈 아게 | Novel binding agents and assays for PIVKA |
| KR20200067193A (en) | 2017-10-20 | 2020-06-11 | 에프. 호프만-라 로슈 아게 | Copy protection against antibodies |
| WO2019108755A1 (en) | 2017-11-30 | 2019-06-06 | Genentech, Inc. | Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1 |
| EP3492460A1 (en) * | 2017-12-01 | 2019-06-05 | Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. | Compounds for separation of rare earth elements, method of separation, and use thereof |
| KR20200131838A (en) | 2018-03-14 | 2020-11-24 | 에프. 호프만-라 로슈 아게 | Methods for affinity maturation of antibodies |
| JP7734487B2 (en) | 2018-03-14 | 2025-09-05 | エフ． ホフマン－ラ ロシュ アーゲー | Novel anti-troponin T antibody |
| CN111936522B (en) | 2018-04-18 | 2024-07-02 | 豪夫迈·罗氏有限公司 | Novel anti-thymidine kinase antibody |
| EP3844503B1 (en) | 2018-08-31 | 2024-05-29 | F. Hoffmann-La Roche AG | Thymidine kinase (tk-1) in prognostic indices for dlbcl |
| US20220001043A1 (en) | 2018-09-28 | 2022-01-06 | Imaginab, Inc. | Cd8 imaging constructs and methods of use thereof |
| EP3747852B1 (en) | 2019-06-05 | 2022-10-26 | Ustav organicke chemie a biochemie AV CR, v.v.i. | Compounds for chromatographic separation of rare earth elements and s-, p-, d- metals, method of separation, and use thereof |
| BR112022000945A2 (en) | 2019-07-22 | 2022-03-08 | Hoffmann La Roche | Methods for assessing whether a patient has endometriosis or is at risk of developing endometriosis, for selecting a patient for therapy, and for monitoring a patient who has endometriosis or is being treated for endometriosis |
| WO2021013786A1 (en) | 2019-07-22 | 2021-01-28 | F. Hoffmann-La Roche Ag | S100a6 as blood biomarker for the non-invasive diagnosis of endometriosis |
| CN114144675A (en) | 2019-07-22 | 2022-03-04 | 豪夫迈·罗氏有限公司 | S100A9 as a blood biomarker for non-invasive diagnosis of endometriosis |
| BR112022001140A2 (en) | 2019-07-22 | 2022-03-15 | Hoffmann La Roche | Methods for assessing whether a patient has endometriosis or is at risk of developing endometriosis, selecting a patient for therapy, and monitoring a patient suffering from endometriosis or being treated for endometriosis |
| JP7315780B2 (en) | 2019-07-22 | 2023-07-26 | エフ． ホフマン－ラ ロシュ アーゲー | Substance P as a blood biomarker for non-invasive diagnosis of endometriosis |
| KR20220100883A (en) | 2019-11-15 | 2022-07-18 | 에프. 호프만-라 로슈 아게 | Derivatization of Beta-Lactam Antibiotics for Mass Spectrometry Determination of Patient Samples |
| EP4237855A1 (en) | 2020-10-30 | 2023-09-06 | F. Hoffmann-La Roche AG | Timp1 as a marker for cholangiocarcinoma |
| CN116829951A (en) | 2020-11-02 | 2023-09-29 | 豪夫迈·罗氏有限公司 | SARS-CoV-2 nucleocapsid antibodies |
| WO2022207628A1 (en) | 2021-03-30 | 2022-10-06 | F. Hoffmann-La Roche Ag | Scf as blood biomarker for the non-invasive diagnosis of endometriosis |
| WO2022207685A1 (en) | 2021-04-01 | 2022-10-06 | F. Hoffmann-La Roche Ag | Psp94 as blood biomarker for the non-invasive diagnosis of endometriosis |
| US20240272177A1 (en) | 2021-05-17 | 2024-08-15 | Roche Diagnostics Operations, Inc. | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS |
| WO2023072904A1 (en) | 2021-10-26 | 2023-05-04 | F. Hoffmann-La Roche Ag | Monoclonal antibodies specific for sars-cov-2 rbd |
| EP4448564A1 (en) | 2021-12-17 | 2024-10-23 | F. Hoffmann-La Roche AG | A novel antibody for detection of amyloid beta 42 (a-beta42) |
| WO2023131594A1 (en) | 2022-01-05 | 2023-07-13 | F. Hoffmann-La Roche Ag | Derivatization of compounds in patient samples for therapeutic drug monitoring (tdm) |
| WO2023247752A1 (en) | 2022-06-23 | 2023-12-28 | F. Hoffmann-La Roche Ag | Method for diagnosing endometriosis and for classifying the stage of endometriosis |
| CN119585617A (en) | 2022-07-22 | 2025-03-07 | 豪夫迈·罗氏有限公司 | Meteorin-like protein (METRNL) as a (blood) biomarker for the diagnosis of polycystic ovary syndrome |
| CN119604768A (en) | 2022-07-22 | 2025-03-11 | 豪夫迈·罗氏有限公司 | Leukotriene A4 hydrolase (LTA4H) as a (blood) biomarker for the diagnosis of polycystic ovary syndrome |
| JP2025523884A (en) | 2022-07-22 | 2025-07-25 | エフ． ホフマン－ラ ロシュ アーゲー | Fibroblast growth factor binding protein 1 (FGFBP1) as a (blood) biomarker for the diagnosis of polycystic ovary syndrome |
| EP4565570A1 (en) * | 2022-08-01 | 2025-06-11 | Portland State University | High relaxivity contrast agents and stereoselective preparation |
| WO2025026908A1 (en) | 2023-07-28 | 2025-02-06 | Roche Diagnostics Gmbh | Serum epha1 as biomarker for endometriosis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2609390A (en) * | 1950-06-01 | 1952-09-02 | Frederick C Bersworth | Phosphonic alkylene polyamino acids and method of producing same |
| US3336221A (en) * | 1964-11-05 | 1967-08-15 | Calgon Corp | Method of inhibiting precipitation and scale formation |
| US3331773A (en) * | 1966-07-22 | 1967-07-18 | Grace W R & Co | Process for inhibiting precipitation in water |
| US3434969A (en) * | 1967-08-11 | 1969-03-25 | Calgon Corp | Scale inhibiting |
| US4980148A (en) * | 1985-02-06 | 1990-12-25 | Mallinckrodt, Inc. | Methods for enhancing magnetic resonance imaging |
| US4880008A (en) * | 1985-05-08 | 1989-11-14 | The General Hospital Corporation | Vivo enhancement of NMR relaxivity |
| US4899755A (en) * | 1985-05-08 | 1990-02-13 | The General Hospital Corporation | Hepatobiliary NMR contrast agents |
| AU634167B2 (en) * | 1988-06-24 | 1993-02-18 | Dow Chemical Company, The | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
| US5247077A (en) * | 1989-06-23 | 1993-09-21 | Celltech Limited | Tri-aza macrocycles and processes for their preparation |
| GB8914543D0 (en) * | 1989-06-23 | 1989-08-09 | Parker David | Chemical compounds |
| FR2672051B1 (en) * | 1991-01-24 | 1993-05-21 | Guerbet Sa | NOVEL NITROGEN MACROCYCLIC LIGANDS, PREPARATION METHOD, POLYMETALLIC COMPLEXES, DIAGNOSTIC AND THERAPEUTIC COMPOSITION. |
| IL106159A0 (en) * | 1992-06-30 | 1993-10-20 | Dow Chemical Co | Targeted delivery of growth factors for bone regeneration |
| EP0588229A3 (en) * | 1992-09-12 | 1994-06-15 | Hoechst Ag | Macrocyclic chelating agents for the preparation of technetium or rhenium complexes |
-
1993
- 1993-05-06 US US08/057,588 patent/US5462725A/en not_active Expired - Fee Related
-
1994
- 1994-05-05 CN CN94192527.7A patent/CN1125905A/en active Pending
- 1994-05-05 AT AT94917922T patent/ATE227297T1/en not_active IP Right Cessation
- 1994-05-05 CA CA002162174A patent/CA2162174A1/en not_active Abandoned
- 1994-05-05 JP JP6525558A patent/JPH08510245A/en not_active Ceased
- 1994-05-05 AU AU69447/94A patent/AU678583B2/en not_active Ceased
- 1994-05-05 EP EP94917922A patent/EP0711300B1/en not_active Expired - Lifetime
- 1994-05-05 DE DE69431660T patent/DE69431660T2/en not_active Expired - Fee Related
- 1994-05-05 FI FI955319A patent/FI955319A7/en unknown
- 1994-05-05 SG SG1996004873A patent/SG46458A1/en unknown
- 1994-05-05 HU HU9503174A patent/HUT74565A/en unknown
- 1994-05-05 WO PCT/US1994/005009 patent/WO1994026275A1/en not_active Ceased
- 1994-05-05 CZ CZ952895A patent/CZ289595A3/en unknown
- 1994-05-05 PL PL94311643A patent/PL311643A1/en unknown
-
1995
- 1995-11-06 NO NO954440A patent/NO301829B1/en unknown
- 1995-12-05 BG BG100192A patent/BG100192A/en unknown
- 1995-12-06 LV LVP-95-362A patent/LV11430B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LV11430B (en) | 1997-04-20 |
| EP0711300A4 (en) | 1996-03-12 |
| NO954440L (en) | 1996-01-05 |
| AU678583B2 (en) | 1997-06-05 |
| NO954440D0 (en) | 1995-11-06 |
| BG100192A (en) | 1996-12-31 |
| SG46458A1 (en) | 1998-02-20 |
| EP0711300A1 (en) | 1996-05-15 |
| JPH08510245A (en) | 1996-10-29 |
| DE69431660T2 (en) | 2003-08-21 |
| PL311643A1 (en) | 1996-03-04 |
| US5462725A (en) | 1995-10-31 |
| CZ289595A3 (en) | 1997-01-15 |
| HU9503174D0 (en) | 1996-01-29 |
| EP0711300B1 (en) | 2002-11-06 |
| HUT74565A (en) | 1997-01-28 |
| DE69431660D1 (en) | 2002-12-12 |
| ATE227297T1 (en) | 2002-11-15 |
| CN1125905A (en) | 1996-07-03 |
| FI955319A0 (en) | 1995-11-06 |
| AU6944794A (en) | 1994-12-12 |
| CA2162174A1 (en) | 1994-11-24 |
| WO1994026275A1 (en) | 1994-11-24 |
| FI955319A7 (en) | 1995-12-22 |
| NO301829B1 (en) | 1997-12-15 |
| LV11430A (en) | 1996-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI955319A7 (en) | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, their complexes and derivatives for use as antibodies | |
| FI955336L (en) | Tricyclopolyazamacrocyclophosphonic acids, their complexes and derivatives used as contrast agents | |
| FI941137A7 (en) | 2-Debenzoyl-2-acyltaxol derivatives and methods for their preparation | |
| FI940904L (en) | Oxazolidinedione derivatives, their preparation and use | |
| FI925913L (en) | Method for polymerizing -olefins, as well as prepolymerized catalyst composition and method for preparing the same | |
| FI945281L (en) | Heterocyclic compounds, their preparation and use | |
| FI924054A7 (en) | Imidazole-linked iso- and heterocycles, method for their preparation and use | |
| FI963298L (en) | Hydroxemic acid and carboxylic acid derivatives, method for their preparation and use | |
| FI954979A7 (en) | 10,11-Methanedibenzosuberane derivatives used as chemosensitizers | |
| FI943687L (en) | New 11-benzaldoxime estradiene derivatives, methods for their preparation and pharmaceuticals containing these compounds | |
| FI932282L (en) | PROTEIN C DERIVATIVES | |
| FI920017A7 (en) | Azole derivatives, methods for their preparation and their use | |
| FI951468L (en) | Lipopeptide derivatives, method for their preparation and use | |
| CY2013003I2 (en) | PHOSPHONOCHEMICAL DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | |
| FI935465L (en) | Thermoplastic composition, method for its preparation and use | |
| FI953919A7 (en) | Pyrrolydenemethyl derivatives and process for their preparation | |
| FI935887L (en) | Thiazolidinedione derivatives, their preparation and use | |
| FI944417L (en) | Azole compounds, their preparation and use | |
| FI915381A7 (en) | Substituted azoles, process for their preparation and use | |
| FI944713L (en) | 4-Diphenylmethylpiperidine derivatives and process for their preparation | |
| FI951631L (en) | Substituted kynurenines, method for their preparation and their use as medicaments | |
| FI923755A7 (en) | Disulfides, methods for their preparation and their use | |
| FI954229L (en) | Heterocyclic compounds, their use and preparation | |
| FI933544A7 (en) | Thiadiazinecarboxamide derivatives, processes for their preparation and pharmaceuticals | |
| FI933507A7 (en) | Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates for use as contrast agents and method for their preparation |